Mitchell Dowsett

Cancer Research · 2003–2020

A researcher in the Science corpus: 37 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

• Cancer Research — 198 citations into it; #1,478 of 1,780 by trust here, #119 by citations
• Genetics — 122 citations into it; #5,961 of 6,854 by trust here, #483 by citations

Whom Mitchell Dowsett trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Jack Cuzick

Who trusts Mitchell Dowsett overall

1. Torsten O. Nielsen
2. Hodgkin Lymphoma
3. Balazs Acs
4. Jack Cuzick
5. E. Inwald
6. Christine L. Ferguson
7. E. Musgrove

Papers from Mitchell Dowsett's perspective

Ordered by how strongly the researchers Mitchell Dowsett trusts endorse each paper. Same corpus, a different order for every researcher.

1. Expert Commentary. (Histopathology)
2. A gene-expression signature as a predictor of survival in breast cancer. (New England Journal of Medicine)
3. Proliferation marker Ki-67 in early breast cancer. (Journal of Clinical Oncology)
4. Aromatase inhibitors in breast cancer. (New England Journal of Medicine)
5. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. (Journal of Clinical Oncology)
6. Validation of Tissue Microarray Technology in Breast Carcinoma (Laboratory Investigation)
7. Quantification of immunohistochemistry—issues concerning methods, utility and semiquantitative assessment II (Histopathology)
8. The Ki‐67 protein: From the known and the unknown
9. Globocan 2000 : cancer incidence, mortality and prevalence worldwide
10. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. (Molecular Endocrinology)

Their papers

• Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. (2011) — 1,714 citations
• A randomised phase III trial of carboplatin compared with docetaxel in BRCA1/2 mutated and pre-specified triple negative breast cancer “BRCAness” subgroups: the TNT Trial (2018) — 811 citations
• Proliferation marker Ki-67 in early breast cancer. (2005) — 766 citations
• Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. (2020) — 1,200 citations
• Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group (2020) — 663 citations
• Patient-derived organoids model treatment response of metastatic gastrointestinal cancers (2018) — 1,767 citations
• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. (2018) — 1,382 citations
• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. (2018) — 1,800 citations
• Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (2018) — 913 citations
• 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years (2017) — 1,475 citations
• Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer (2016) — 628 citations
• Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. (2016) — 639 citations
• Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer (2015) — 1,077 citations
• Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. (2015) — 628 citations
• Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. (2015) — 1,174 citations
• Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. (2013) — 624 citations
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. (2013) — 4,808 citations
• Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. (2011) — 724 citations
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials (2011) — 2,726 citations
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). (2010) — 894 citations